u/camila_kowalski

modmail first, always, and the thread second

Small fix — archiving happens at a year, not at six months. It is in the published policy.

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

Feed position is a function of early votes and time. That structurally favours agreeable early answers over correct late ones, which is why sorting by controversial occasionally is worth the effort.

Does the effect persist with continued dosing or does tolerance develop?

Vendor source pages carry an outbound link to the supplier’s own storefront, marked nofollow and sponsored, disclosed on the page and again on the funding page. Nothing is received for it.

glucagon agonism sounds paradoxical until you read the energy expenditure work

What was the exposure in that experiment relative to therapeutic?

Is there any human data on that mechanism yet?

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

Cosigning on GIP.

This is the concept everything else on this board is downstream of.

Is that from a human study or a preclinical model?

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

Inter-lab variance on this assay runs roughly a point either way, driven mostly by gradient and integration. Two results inside that band agree; they do not disagree quietly.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

Date of analysis anchors the result to a manufacturing period. A two-year-old result is evidence about two years ago and should be read that way.

I would not archive earlier. The old threads are the most-searched thing on the site.

the log is cumulative, that is the whole value of it

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

Complained about a rule without proposing anything and was politely pointed at this page. Fair.

Which rule specifically, and which part of it?

Sorted by controversial for a week and found four of the best threads I have read here.

Area percent and net peptide content are different measurements and most reports give one. Quote which, or the comparison downstream is meaningless.

Date of analysis anchors the result to a manufacturing period. A two-year-old result is evidence about two years ago and should be read that way.

First result I ever posted here got asked for the batch number and the claim. Fair, and my posts have been better ever since.

What is the concrete wording you would replace it with?

Sent a vial in specifically to check a supplier’s claim after a good experience. It matched. Boring result, worth logging.

Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.

the ranking formula is published, go and read it

This is the principle the whole site is built on. Publish it or do not enforce it.

mechanism explains a direction, not a magnitude

vendor, compound, batch, service, result — that is the template

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

Read the ranking formula out of scepticism and reproduced the ordering in a spreadsheet. It does what it says.

Right, and the storefront links on source pages are marked and disclosed, which is the honest way to do it.

Speculation is welcome here if it is labelled.

sig_figs_sam is right that mechanism gives direction and not magnitude. Worth pinning.

glucagon agonism sounds paradoxical until you read the energy expenditure work

The ranking functions are published: the hot ordering combines score magnitude with age, and the controversial ordering weights total volume by the balance between up and down votes. Both are reproducible from the numbers on each submission.

Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.